From a clinically relevant pain target to a possible analgesic treatment strategy.
作者信息
Latremoliere Alban
机构信息
Department of Neurosurgery, Neurosurgery Pain Research Institute, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
出版信息
Neurotherapeutics. 2025 Mar;22(2):e00542. doi: 10.1016/j.neurot.2025.e00542. Epub 2025 Feb 5.
Abstract
摘要
相似文献
1
From a clinically relevant pain target to a possible analgesic treatment strategy.从临床相关的疼痛靶点到一种可能的镇痛治疗策略。
Neurotherapeutics. 2025 Mar;22(2):e00542. doi: 10.1016/j.neurot.2025.e00542. Epub 2025 Feb 5.
2
Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.表型药物筛选揭示代谢 GCH1/BH4 途径是 EGFR/KRAS 介导的神经性疼痛和肺癌的关键调节因子。
Sci Transl Med. 2022 Aug 31;14(660):eabj1531. doi: 10.1126/scitranslmed.abj1531.
3
Effective relief of neuropathic pain by adeno-associated virus-mediated expression of a small hairpin RNA against GTP cyclohydrolase 1.腺相关病毒介导的 GTP 环水解酶 1 短发夹 RNA 表达对神经病理性疼痛的有效缓解。
Mol Pain. 2009 Nov 18;5:67. doi: 10.1186/1744-8069-5-67.
4
Inhibition of GTP cyclohydrolase reduces cancer pain in mice and enhances analgesic effects of morphine.抑制 GTP 环水解酶可减轻小鼠的癌痛，并增强吗啡的镇痛效果。
J Mol Med (Berl). 2012 Dec;90(12):1473-86. doi: 10.1007/s00109-012-0927-7. Epub 2012 Jun 17.
5
GCH1 variants, tetrahydrobiopterin and their effects on pain sensitivity.GCH1基因变异、四氢生物蝶呤及其对疼痛敏感性的影响。
Scand J Pain. 2014 Apr 1;5(2):121-128. doi: 10.1016/j.sjpain.2013.12.001.
6
Overexpression of miR-133a-3p reduces microglia activation by binding to GCH1, alleviating neuroinflammation and neuropathic pain.miR-133a-3p的过表达通过与GCH1结合来减少小胶质细胞的激活，减轻神经炎症和神经性疼痛。
Exp Brain Res. 2024 Dec 12;243(1):23. doi: 10.1007/s00221-024-06956-y.
7
Impaired behavioural pain responses in hph-1 mice with inherited deficiency in GTP cyclohydrolase 1 in models of inflammatory pain.在炎症性疼痛模型中，GTP 环化水解酶 1 遗传性缺乏的 hph-1 小鼠表现出行为性疼痛反应受损。
Mol Pain. 2013 Feb 19;9:5. doi: 10.1186/1744-8069-9-5.
8
GCH1, BH4 and pain.GCH1、BH4 和疼痛。
Curr Pharm Biotechnol. 2011 Oct;12(10):1728-41. doi: 10.2174/138920111798357393.
9
Cross-species RNAi therapy via AAV delivery alleviates neuropathic pain by targeting GCH1.通过腺相关病毒载体递送进行的跨物种RNA干扰疗法通过靶向GCH1减轻神经性疼痛。
Neurotherapeutics. 2025 Mar;22(2):e00511. doi: 10.1016/j.neurot.2024.e00511. Epub 2024 Dec 14.
10
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence.鸟苷三磷酸环化水解酶和四氢生物蝶呤调节疼痛敏感性和持续性。
Nat Med. 2006 Nov;12(11):1269-77. doi: 10.1038/nm1490. Epub 2006 Oct 22.
本文引用的文献
1
Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain.舒泽曲明的药理学及作用机制，一种用于治疗中重度疼痛的强效选择性Na1.8疼痛信号抑制剂
Pain Ther. 2025 Apr;14(2):655-674. doi: 10.1007/s40122-024-00697-0. Epub 2025 Jan 8.
2
Cross-species RNAi therapy via AAV delivery alleviates neuropathic pain by targeting GCH1.通过腺相关病毒载体递送进行的跨物种RNA干扰疗法通过靶向GCH1减轻神经性疼痛。
Neurotherapeutics. 2025 Mar;22(2):e00511. doi: 10.1016/j.neurot.2024.e00511. Epub 2024 Dec 14.
3
Na1.8 inhibitor poised to provide opioid-free pain relief.钠通道1.8抑制剂有望实现无阿片类药物的疼痛缓解。
Nat Rev Drug Discov. 2025 Jan;24(1):3-5. doi: 10.1038/d41573-024-00203-3.
4
Selective Inhibition of Na1.8 with VX-548 for Acute Pain.选择性抑制钠通道 Na1.8 治疗急性疼痛的研究进展：VX-548 为代表的新型钠离子通道阻滞剂。
N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870.
5
Peripheralized sepiapterin reductase inhibition as a safe analgesic therapy.外周化蝶呤还原酶抑制作为一种安全的镇痛疗法。
Front Pharmacol. 2023 May 12;14:1173599. doi: 10.3389/fphar.2023.1173599. eCollection 2023.
6
Are catechol-O-methyltransferase gene polymorphisms genetic markers for pain sensitivity after all? - A review and meta-analysis.儿茶酚氧位甲基转移酶基因多态性是否真的是所有疼痛敏感性的遗传标志物？——综述和荟萃分析。
Neurosci Biobehav Rev. 2023 May;148:105112. doi: 10.1016/j.neubiorev.2023.105112. Epub 2023 Feb 24.
7
Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations.优化与加速慢性疼痛精准治疗的发展：IMMPACT综述与建议
J Pain. 2023 Feb;24(2):204-225. doi: 10.1016/j.jpain.2022.08.010. Epub 2022 Oct 2.
8
Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.表型药物筛选揭示代谢 GCH1/BH4 途径是 EGFR/KRAS 介导的神经性疼痛和肺癌的关键调节因子。
Sci Transl Med. 2022 Aug 31;14(660):eabj1531. doi: 10.1126/scitranslmed.abj1531.
9
Na1.7 target modulation and efficacy can be measured in nonhuman primate assays.纳 1.7 靶点的调节和疗效可以在非人类灵长类动物的实验中进行测量。
Sci Transl Med. 2021 May 19;13(594). doi: 10.1126/scitranslmed.aay1050.
10
Neuropathic Pain: From Mechanisms to Treatment.神经病理性疼痛：从机制到治疗。
Physiol Rev. 2021 Jan 1;101(1):259-301. doi: 10.1152/physrev.00045.2019. Epub 2020 Jun 25.
Zotero 插件